Please login to the form below

Not currently logged in
Email:
Password:

GSK partners with Singapore research agency on emerging markets

Will work with A*STAR’s Institute of Chemical and Engineering to research reformulated medicines

Will work with A*STAR's Institute of Chemical and Engineering to research reformulated medicines

GlaxoSmithKline (GSK) is to partner with Singapore's lead government agency for research to develop new formulations of existing medicines specifically for emerging markets.

The UK-based pharma company will work with the Agency for Science, Technology and Research's (A*STAR) Institute of Chemical and Engineering Sciences over the next five years to research reformulated medicines, taking advantage of a growing demand for pharmaceutical products in emerging markets, including China, Brazil, India and Russia.

It expands on an existing relationship between A*STAR and GSK that began in 2003 and includes a 2012 agreement with the Agency's Genome Institute of Singapore (GIS) to research treatments for lung cancer.

The latest deal for evidence-based formulations (EBFs) reinforces Singapore as both GSK's hub for emerging markets and an important base for the pharma industry, as companies look towards growth in nearby countries, including Indonesia, India and Vietnam.

Duncan McKay, VP, emerging markets & Asia Pacific R&D, GSK, said the agreement was part of the company's strategy of “growing a diversified global business”.

He said: “Within GSK's portfolio of off-patent products, EBFs are an important part of our growth strategy, and our hope is that together with the Institute of Chemical and Engineering Sciences, we will create a sustainable, scalable model to meet both specific market conditions and patient requirements.”

Kevin Lai, director of biomedical sciences for Singapore's Economic Development Board, gave the government perspective.

“This is a strong endorsement of Singapore's scientific talent and capabilities,” he said. “It also further reinforces Singapore's offering as the base for companies to generate insights and develop new solutions and market access strategies for the fast growing emerging markets.”

9th April 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....